

Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

17 April 2017

DEPARTMENT MEMORANDUM

No. 2017- 0174

FOR: SECRETARY OF HEALTH OF AUTONOMOUS REGION IN MUSLIM MINDANAO (ARMM) AND ALL DOH REGIONAL DIRECTORS

SUBJECT: Harmonization of the National Tuberculosis Control Program (NTP) – Programmatic Indicators with Field Health Services Information System (FHSIS)


The National Tuberculosis Control Program (NTP) has recently updated its indicators to align with the 2017 – 2022 Philippine Strategic TB Elimination Plan Phase 1 and End TB Strategy of the World Health Organization (WHO). As such the indicators of Field Health Services Information System are also being updated. Please see attached document.

In line with this, all DOH Central Offices, Regional Offices, Provincial/District/City/Municipal Health Offices, DOH retained facilities and Local Government Units with health facilities (barangay health stations and rural health units) are hereby informed of the new programmatic indicators of TB for FHSIS.

For Quarter 1 and Quarter 2 of 2017, DOTS facilities will be collaborating with the FHSIS coordinator in sharing the copy of the Integrated Tuberculosis Information System (ITIS) generated Report 3a, Report 3b, 5a and 5c. For Quarter 3 onwards, a control button will be developed to electronically send the data from ITIS to iClinicSys (FHSIS).

For compliance.

By Authority of the Secretary of Health:



GERARDO V. BAYUGO, MD, MPH, CESO III
Undersecretary of Health
Office for Technical Services

Indicator	Definition	Formula	Source of Data	Frequency of Reporting	Counterpart NTP Report
1. Presumptive TB Tested	Number of presumptive TB tested using primary TB diagnostic tool (DSSM or Xpert MTB/RIF) Presumptive TB – any person whether adult or child with signs and/or symptoms suggestive of TB whether pulmonary or extrapulmonary, or those with chest x-ray findings suggestive of active TB Tested – examined and with recorded laboratory result Primary TB diagnostic tool – use of Direct Sputum Smear Microscopy or Xpert MTB/RIF depending on risk group of patient	Among the number of presumptive TB screened, number with recorded laboratory result in the Presumptive TB Masterlist	NTP Presumptive Masterlist	Quarterly	<ul style="list-style-type: none"> 2017 Revised Report 3a. (A.2) Total Number of Presumptive TB Tested
2. Percentage of Presumptive TB Tested using WRD	Number of presumptive TB tested using WHO-recommended Rapid Diagnostic Test (ie, Xpert MTB/RIF) among Number of Presumptive TB in the same year, expressed as a percentage	Numerator = Number with recorded Xpert result in the Presumptive TB Masterlist Denominator = Number of Presumptive TB recorded in the Masterlist	NTP Presumptive Masterlist	Quarterly	<ul style="list-style-type: none"> 2017 Revised Report 3a. (A.2) Total Number of Presumptive TB Tested
3. New Cases Treated	Number of New Cases notified and treated New – A patient who has never had treatment for TB* or who has taken anti-TB drugs for less than one (<1) month	Number of New Cases notified and treated, whether bacteriologically-confirmed or clinically-diagnosed, pulmonary or extra-pulmonary, and drug-susceptible or drug-resistant	Drug-susceptible TB Register and Drug-resistant TB Register	Quarterly	<ul style="list-style-type: none"> 2017 Revised Report 3a. (B) Bacteriologically-confirmed Pulmonary and Extrapulmonary New + (C) Clinically-diagnosed Pulmonary and Extrapulmonary New 2017 Revised Report 3b. (B) DRTB Cases Registered New
4. Release Cases Treated	Number of Relapse Cases notified and treated Relapse – A patient Retreatment for TB, who has been declared cured or treatment completed in their most recent treatment	Number of Relapse Cases notified and treated, whether bacteriologically-confirmed or clinically-diagnosed, pulmonary or extra-pulmonary, and drug-susceptible or drug-resistant	Drug-susceptible TB Register and Drug-resistant TB Register	Quarterly	<ul style="list-style-type: none"> 2017 Revised Report 3a. (B) Bacteriologically-confirmed Pulmonary and Extrapulmonary New + (C) Clinically-diagnosed Pulmonary and Extrapulmonary Relapse 2017 Revised Report 3b. (B) DRTB Cases Registered Relapse
5. TB, All Forms Treated	Number of New and Relapse Cases (TB, All Forms) notified and treated All forms= New + Relapse	Number of New + Relapse Cases notified and treated, whether bacteriologically-confirmed or clinically-diagnosed, pulmonary or extra-pulmonary, and drug-susceptible or drug-resistant	Drug-susceptible TB Register and Drug-resistant TB Register	Quarterly	<ul style="list-style-type: none"> 2017 Revised Report 3a. (B) Bacteriologically-confirmed Pulmonary and Extrapulmonary New + (C) Clinically-diagnosed Pulmonary and Extrapulmonary New (B) Bacteriologically-confirmed Pulmonary and Extrapulmonary Relapse + (C) Clinically-diagnosed Pulmonary and Extrapulmonary Relapse 2017 Revised Report 3b. (B) DRTB Cases Registered New + DRTB Cases Registered Relapse

Indicator	Definition	Formula	Source of Data	Frequency of Reporting	Counterpart NTP Report
6. Percentage of TB, All Forms with Bacteriological Confirmation	Number of New and Relapse Cases (TB, All Forms) notified and treated with bacteriological confirmation among TB, All Forms, expressed as a percentage All forms= New + Relapse Bacteriologically-confirmed – A TB patient from whom a biological specimen is positive by smear microscopy, culture or rapid diagnostic tests (such as Xpert MTB/RIF).	Numerator = BC New and Relapse Denominator =BC New and Relapse + CD New and Relapse	Drug-susceptible TB Register and Drug-resistant TB Register	Quarterly	<ul style="list-style-type: none"> 2017 Revised Report 3a. (B) Bacteriologically-confirmed Pulmonary and Extrapulmonary New + (C) Clinically-diagnosed Pulmonary and Extrapulmonary New (B) Bacteriologically-confirmed Pulmonary and Extrapulmonary Relapse + (C) Clinically-diagnosed Pulmonary and Extrapulmonary Relapse 2017 Revised Report 3b. (B) DRTB Cases Registered New + DRTB Cases Registered Relapse
7. Treatment Coverage Rate, All Forms	Number of New and Relapse (DRTB and DSTB, BC and CD, P and EP) cases that were notified and treated, divided by the estimated number of incident TB cases in the same year, expressed as a percentage.	Numerator = Number of Registered New and Relapse Cases, both drug-susceptible and drug-resistant Denominator = Population x Incidence Rate	Numerator: Drug-susceptible TB Register and Drug-resistant TB Register Denominator: WHO Global TB Report and PSA	Quarterly	<ul style="list-style-type: none"> 2017 Revised Report 3a. (B) Bacteriologically-confirmed Pulmonary and Extrapulmonary New + (C) Clinically-diagnosed Pulmonary and Extrapulmonary New (B) Bacteriologically-confirmed Pulmonary and Extrapulmonary Relapse + (C) Clinically-diagnosed Pulmonary and Extrapulmonary Relapse 2017 Revised Report 3b. (B) DRTB Cases Registered New + DRTB Cases Registered Relapse
8. Retreatment Cases (except Relapse) Treated	Number of Retreatment or Previously Treated Cases except Relapse notified and treated Retreatment – A patient who has had treatment for TB or who has taken anti-TB drugs for more than one (>1) month; includes: Relapse, Treatment After Failure, Treatment After Lost to Follow-up and Previous Treatment Outcome Unknown	Number of Previously Treated Cases (except Relapse) notified and treated, whether bacteriologically-confirmed or clinically-diagnosed, pulmonary or extra-pulmonary, and drug-susceptible or drug-resistant	Drug-susceptible TB Register and Drug-resistant TB Register	Quarterly	<ul style="list-style-type: none"> 2017 Revised Report 3a. (B) Bacteriologically-confirmed Pulmonary and Extrapulmonary Previously Treated (except Relapse) + (C) Clinically-diagnosed Pulmonary and Extrapulmonary Previously Treated (except Relapse) 2017 Revised Report 3b. (B) DRTB Cases Registered Previously Treated (except Relapse)

Indicator	Definition	Formula	Source of Data	Frequency of Reporting	Counterpart NTP Report
<p>9. RRTB/ MDRTB/ XDRTB Cases Treated</p>	<p>Number of bacteriologically-confirmed Rifampicin-resistant TB (RRTB), Multidrug-resistant TB (MDRTB), and Extensively Drug-resistant TB (XDRTB) cases notified and treated</p> <p>Bacteriologically-confirmed Rifampicin-resistant TB (BC RR-TB) – a patient with sputum from pulmonary site or biological specimen from extra-pulmonary site that is positive for MTB complex using rapid diagnostic modalities (i.e., Xpert MTB/RIF) with resistance to Rifampicin from an Xpert machine regardless of date of collection, with or without radiographic abnormalities; if patient had previous successful treatment, resistance should be from specimen collected after successful treatment</p> <p>Bacteriologically-confirmed Multidrug-resistant TB (BC MDR-TB) – a patient with sputum from pulmonary site or biological specimen from extra-pulmonary site that is positive for MTB complex with resistance to at least both Isoniazid and Rifampicin from an NTP-recognized laboratory regardless of date of collection, with or without radiographic abnormalities; if patient had previous successful treatment, resistance should be from specimen collected after successful treatment</p> <p>Bacteriologically-confirmed Extensively Drug-resistant TB (BC XDR-TB) – a patient with sputum from pulmonary site or biological specimen from extra-pulmonary site that is positive for MTB complex with resistance to any fluoroquinolone and to at least one of three second-line injectable drugs (Capreomycin, Kanamycin and Amikacin), in addition to multidrug resistance, from an NTP-recognized laboratory regardless of date of collection, with or without radiographic abnormalities; if patient had previous successful treatment, resistance should be from specimen collected after successful treatment.</p>	<p>Number of bacteriologically-confirmed Rifampicin-resistant TB (RRTB) + bacteriologically-confirmed Multidrug-resistant TB (MDRTB) + bacteriologically-confirmed Extensively Drug-resistant TB (XDRTB) cases notified and treated</p>	<p>Drug-resistant TB Register</p>	<p>Quarterly</p>	<ul style="list-style-type: none"> 2017 Revised Report 3b. (B) DRTB Cases Registered Bacteriologically-confirmed RRTB + MDRTB and Bacteriologically-confirmed XDRTB
<p>10. Treatment Success Rate, DSTB All Forms</p>	<p>Number of Drug-susceptible New and Relapse Cases (DSTB, All Forms) from last year who were successfully treated</p> <p>Treatment Success – the sum of cured and treatment completed Cured – A patient with bacteriologically-confirmed TB at the beginning of treatment and who was smear- or culture-negative in the last month of treatment and on at least one previous occasion in the continuation phase</p> <p>Treatment Completed – A patient who completes treatment without evidence of failure but with no record to show that sputum smear or culture results in the last month of treatment and on at least one previous occasion were negative, either because tests were not done or because results are unavailable.</p> <p>This group includes:</p> <ul style="list-style-type: none"> A bacteriologically confirmed patient who has completed treatment but without DSSM follow-up in the last month of treatment and on at least one previous occasion A clinically diagnosed patient who has completed treatment 	<p>Numerator = Success = Cured Drug-susceptible New and Relapse Cases (TB, All Forms) whether bacteriologically-confirmed or clinically-diagnosed and pulmonary or extrapulmonary + Treatment Completed Drug-susceptible New and Relapse Cases (TB, All Forms) whether bacteriologically-confirmed or clinically-diagnosed and pulmonary or extrapulmonary</p> <p>Denominator = Drug-susceptible New and Relapse Cases (TB, All Forms) whether bacteriologically-confirmed or clinically-diagnosed and pulmonary or extrapulmonary notified and treated from 1 year ago</p>	<p>Drug-susceptible TB Register</p>	<p>Quarterly</p>	<ul style="list-style-type: none"> 2017 Revised Report 5a. (A) Bacteriologically-confirmed New and Relapse Cured + (A) Bacteriologically-confirmed New and Relapse Completed + (B) Clinically-diagnosed New and Relapse Completed

Indicator	Definition	Formula	Source of Data	Frequency of Reporting	Counterpart NTP Report
11. Treatment Success Rate, BC RR/MDRTB	<p>Number of notified bacteriologically-confirmed RR-, MDR- and XDR-TB cases from three years ago who were successfully treated</p> <p>Treatment Success – the sum of cured and treatment completed Cured - A patient with bacteriologically-confirmed RR-/MDR-/TB/XDRTB who has completed treatment as recommended by national policy without evidence of failure AND three or more consecutive cultures taken at least thirty (30) days apart are negative after the intensive phase</p> <p>Treatment Completed - A patient who has completed treatment as recommended by national policy without evidence of failure BUT no record that three or more consecutive cultures taken at least thirty (30) days apart are negative after the intensive phase</p>	<p>Numerator = Success = Cured bacteriologically-confirmed RRTB, MDRTB and XDRTB + Treatment Completed bacteriologically-confirmed RRTB, MDRTB and XDRTB</p> <p>Denominator = Number of bacteriologically-confirmed RRTB, MDRTB and XDRTB notified and treated from 3 years ago</p>	<p>Drug-resistant TB Register</p>	<p>Annual</p>	<p>Cohort of patients should be the same:</p> <ul style="list-style-type: none"> 2017 Revised Report 5b of Current Reportable Year. (A) SSTR BC RR/MDR Cured + SSTR BC RR/MDR Completed 2017 Revised Report 5c of Previous Reportable Year. (A) CTR BC RR/MDR Cured + CTR BC RR/MDR Completed + CTR BC XDR Cured + CTR BC XDR Completed